Myricx Bio is a UK biotech company focused on the discovery and development of a novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

Brandon Capital Partners

Sofinnova Partners

Myricx Bio

FUNDING NEWS: We are thrilled to announce our £90m ($114m) series A financing, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners.

The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. 

Having been a virtual company since spinning out from Imperial College London and The Francis Crick Institute, we will now move to establish laboratory operations in London’s biotech hub and will be expanding our management and R&D teams. 

Welcome to our new investors and thank you to everyone that has contributed to the progress of the company so far, not least our founding scientists Ed Tate, Roberto Solari and Andy Bell. Exciting times ahead.

Read the full release HERE https://lnkd.in/eSu9mP3c

#venturecapital #financing #drugdevelopment #UKbiotech

It was a pleasure meeting BiotechTV new European correspondent Amy Brown and explaining our excitement around the prospects for our #NMTi-ADCs. Great to be financed to take two programs into the clinic and further develop our NMTi payload platform.

🎉 #BIAmember Brandon Capital today announced the launch of their sixth fund with a $270 million initial close to drive #LifeScience innovation ➡️ https://ow.ly/u0QS50S89Kn

The new #Fund will support the growth of 🌏 #Australian and #NewZealand #LifeSciences startups, invest in scale-ups, and expand Brandon Capital’s international presence, particularly in the 📍 #UK, #Europe, and the #USA 🚀

More information in the link above 👆

Our CSO, Francesca Zammarchi, is speaking about our novel NMTi payload platform and pre-clinical efficacy studies for our lead ADCs at the ADC Payload Summit, Boston, MA on May 22nd at 12.30pm. 
#drugdiscovery #oncology #cancer  #antibodydrugconjugates

Overall deal flow in biopharma tapered off in 2023 but the big companies sure know what they want, according to a new report from J.P. Morgan.

Looking forward to seeing investors, partners and industry colleagues next week in San Francisco at #JPM24. Lots of positive progress and potential in the #ADC space, so exciting times ahead.

COM:MYRICXBIO

Myricx Bio

Analysis Not Available